Fire Science Conference 'DDW 2023'
Oral and Poster Presentations of Research Results
HK inno.N unveiled new clinical research results on 'K-CAB,' a potassium-competitive acid blocker (P-CAB) class drug for gastroesophageal reflux disease (GERD), at a conference attended by over 20,000 leading gastroenterology experts from around the world.
At the 2023 Digestive Disease Week (DDW 2023), Professor Shin Cheol-min of the Department of Gastroenterology at Bundang Seoul National University Hospital presented the research results of K-CAB tablets. [Photo by HK Innoen]
HK inno.N announced on the 17th that it recently presented the latest research findings on K-CAB (active ingredient: tegoprazan) to domestic and international experts at Digestive Disease Week 2023 (DDW 2023) held in Chicago, USA.
The disclosed data included three studies: ▲a multicenter phase 4 clinical trial confirming the healing rate after 2 and 4 weeks of K-CAB tablet (tegoprazan) administration in patients with erosive reflux disease (ERD), ▲an investigator-initiated clinical trial evaluating the efficacy of K-CAB tablets in patients with iatrogenic ulcers following endoscopic submucosal dissection (ESD), and ▲an investigator-initiated clinical trial assessing changes in gastric emptying after K-CAB administration.
The study on 'healing rates after 2 and 4 weeks of K-CAB tablet (tegoprazan) administration in patients with erosive reflux disease (ERD)' was led by Professor Choi Seok-chae of Wonkwang University Hospital's Department of Gastroenterology, with oral presentation by Professor Shin Cheol-min of Seoul National University Bundang Hospital's Department of Gastroenterology. The results showed that administering 50 mg of K-CAB tablets for 2 and 4 weeks demonstrated non-inferiority compared to the control group receiving proton pump inhibitors (PPIs). Moreover, K-CAB showed similar healing rates regardless of moderate or higher esophagitis severity (LA grade C/D) and CYP2C19 genotype.
The study on 'efficacy of K-CAB tablets in patients with iatrogenic ulcers after endoscopic submucosal dissection (ESD),' led by Professor Park Jong-jae of Korea University Guro Hospital's Department of Gastroenterology, was presented via poster by Professor Kim Byung-wook of Incheon St. Mary's Hospital's Department of Gastroenterology. The results demonstrated that K-CAB was non-inferior to the PPI class drug esomeprazole in treating iatrogenic ulcers and showed a higher healing rate at 4 weeks (30.3% vs. 22.1%).
Endoscopic submucosal dissection (ESD) is an endoscopic treatment method for gastric adenomas or early gastric cancer, and ulcers caused by this procedure are referred to as 'iatrogenic ulcers.' Rapid suppression of gastric acid secretion after ESD is essential for quick ulcer healing and prevention of bleeding and perforation. Through these study results, HK inno.N secured clinical data supporting the therapeutic effect of K-CAB tablets on ulcers.
The results of an investigator-initiated clinical trial on 'changes in gastric emptying after K-CAB tablet administration,' conducted by Professor Jung Hye-kyung of Ewha Womans University Mokdong Hospital's Department of Gastroenterology, were also disclosed via poster. According to Professor Jung's research, PPIs affect the digestive process and have the disadvantage of delaying gastric emptying of food during normal meals. In contrast, K-CAB tablets, a P-CAB class drug, did not significantly affect gastric emptying during meals in healthy adults and did not influence dyspeptic symptoms such as postprandial fullness or early satiety.
Kwok Dal-won, CEO of HK inno.N, stated, "K-CAB is a representative product that created the P-CAB market in South Korea and consistently reveals the latest research results at major global academic conferences such as Digestive Disease Week (DDW) and the United European Gastroenterology Week (UEGW). We are conducting various differentiated studies to enhance the competitiveness of this new drug not only domestically but also in the global market, and we will widely promote the value of K-CAB through continuous clinical research and publication of papers."
Meanwhile, the new drug K-CAB for gastroesophageal reflux disease holds the most indications among domestic drugs in the same class, including ▲erosive reflux disease ▲non-erosive reflux disease ▲gastric ulcers ▲antibiotic combination therapy for Helicobacter pylori eradication ▲maintenance therapy after erosive reflux disease treatment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
